中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Influence of triglyceride/high-density lipoprotein cholesterol ratio on the onset of primary liver cancer

DOI: 10.12449/JCH240418
Research funding:

2023 Medical Science Research Project Plan of Hebei Province (20231865)

More Information
  • Corresponding author: CAO Liying, caoliying@kailuan.com.cn (ORCID: 0000-0003-3662-5961)
  • Received Date: 2023-07-15
  • Accepted Date: 2023-09-11
  • Published Date: 2024-04-25
  •   Objective  To investigate the influence of triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio on the onset of primary liver cancer.  Methods  A prospective cohort study was conducted. Physical examination data were collected from 99 750 cases of on-the-job and retired employees of Kailuan Group who participated health examination from July 2006 to December 2007, and they were followed up till December 31, 2021 to observe the onset of primary liver cancer. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the Kruskal-Wallis H test was used for comparison of continuous data with skewed distribution between multiple groups; the chi-square test was used for comparison of categorical data between groups. According to the tertiles of TG/HDL-C ratio, the subjects were divided into Q1, Q2, and Q3 groups, and the incidence density of primary liver cancer was calculated for each group. The Kaplan-Meier method was used to calculate the cumulative incidence rate of primary liver cancer in each group, and the log-rank test was used to compare the difference in cumulative incidence rate between groups. The Cox proportional hazards model was used to analyze the influence of TG/HDL-C ratio on the onset of primary liver cancer.  Results  There were significant differences between the three groups in age, proportion of male subjects, waist circumference, body mass index, fasting blood glucose, systolic pressure, diastolic pressure, triglyceride, total cholesterol, HDL-C, low-density lipoprotein cholesterol, alanine aminotransferase, high-sensitivity C-reactive protein, chronic liver diseases, hypertension, diabetes, the family history of malignant tumor, drinking, smoking, physical exercise, and educational level (P<0.05). During the mean follow-up time of 14.06±2.71 years, there were 484 cases of new-onset liver cancer, among whom there were 446 male subjects and 38 female subjects. The incidence density of primary liver cancer was 0.39/1 000 person-years in the Q1 group, 0.35/1 000 person-years in the Q2 group, and 0.30/1 000 person-years in the Q3 group, and the cumulative incidence rates of primary liver cancer in the three groups were 6.03‰, 5.28‰, and 4.49‰, respectively, with a significant difference between the three groups based on the long-rank test (χ2=6.06, P=0.048). After adjustment for the confounding factors considered, the Cox proportional hazards model showed that compared with the Q3 group, the Q1 group had a hazard ratio of 2.04 (95% confidence interval [CI]: 1.61‍ ‍—‍ ‍2.58, Pfor trend<0.05), and the Q2 group had a hazard ratio of 1.53 (95%CI: 1.21‍ ‍—‍ ‍1.92, Pfor trend<0.05).  Conclusion  The reduction in TG/HDL-C ratio is associated with an increase in the rask of primary liver cancer, especially in people with chronic liver diseases.

     

  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
    [2]
    FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391( 10127): 1301- 1314. DOI: 10.1016/S0140-6736(18)30010-2
    [3]
    MCGLYNN KA, PETRICK JL, EL-SERAG HB. Epidemiology of hepatocellular carcinoma[J]. Hepatology, 2021, 73( Suppl 1): 4- 13. DOI: 10.1002/hep.31288.
    [4]
    HUANG DQ, EL-SERAG HB, LOOMBA R. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 4): 223- 238. DOI: 10.1038/s41575-020-00381-6.
    [5]
    HANAHAN D. Hallmarks of cancer: New dimensions[J]. Cancer Discov, 2022, 12( 1): 31- 46. DOI: 10.1158/2159-8290.CD-21-1059.
    [6]
    BOROUGHS LK, DEBERARDINIS RJ. Metabolic pathways promoting cancer cell survival and growth[J]. Nat Cell Biol, 2015, 17( 4): 351- 359. DOI: 10.1038/ncb3124.
    [7]
    GANJALI S, BANACH M, PIRRO M, et al. HDL and cancer-causality still needs to be confirmed? Update 2020[J]. Semin Cancer Biol, 2021, 73: 169- 177. DOI: 10.1016/j.semcancer.2020.10.007.
    [8]
    GIANNINI C, SANTORO N, CAPRIO S, et al. The triglyceride-to-HDL cholesterol ratio: Association with insulin resistance in obese youths of different ethnic backgrounds[J]. Diabetes Care, 2011, 34( 8): 1869- 1874. DOI: 10.2337/dc10-2234.
    [9]
    GASEVIC D, FROHLICH J, JOHN MANCINI GB, et al. The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort[J]. Metabolism, 2012, 61( 4): 583- 589. DOI: 10.1016/j.metabol.2011.09.009.
    [10]
    TURAK O, AFŞAR B, OZCAN F, et al. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict new cardiovascular events in essential hypertensive patients[J]. J Clin Hypertens(Greenwich), 2016, 18( 8): 772- 777. DOI: 10.1111/jch.12758.
    [11]
    MILLER M, STONE NJ, BALLANTYNE C, et al. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association[J]. Circulation, 2011, 123( 20): 2292- 2333. DOI: 10.1161/CIR.0b013e3182160726.
    [12]
    HE S, WANG S, CHEN XP, et al. Higher ratio of triglyceride to high-density lipoprotein cholesterol may predispose to diabetes mellitus: 15-year prospective study in a general population[J]. Metabolism, 2012, 61( 1): 30- 36. DOI: 10.1016/j.metabol.2011.05.007.
    [13]
    FAN NG, PENG L, XIA ZH, et al. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: A cross-sectional study[J]. Lipids Health Dis, 2019, 18( 1): 39. DOI: 10.1186/s12944-019-0986-7.
    [14]
    WU SL, HUANG ZR, YANG XC, et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city[J]. Circ Cardiovasc Qual Outcomes, 2012, 5( 4): 487- 493. DOI: 10.1161/CIRCOUTCOMES.111.963694.
    [15]
    CHEW NWS, NG CH, TAN DJH, et al. The global burden of metabolic disease: Data from 2000 to 2019[J]. Cell Metab, 2023, 35( 3): 414- 428. e 3. DOI: 10.1016/j.cmet.2023.02.003.
    [16]
    LI J, ZOU BY, YEO YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4( 5): 389- 398. DOI: 10.1016/S2468-1253(19)30039-1.
    [17]
    NDERITU P, BOSCO C, GARMO H, et al. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort[J]. Int J Cancer, 2017, 141( 6): 1148- 1160. DOI: 10.1002/ijc.30818.
    [18]
    WELZEL TM, GRAUBARD BI, ZEUZEM S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-Medicare database[J]. Hepatology, 2011, 54( 2): 463- 471. DOI: 10.1002/hep.24397.
    [19]
    XIA B, PENG JJ, ENRICO DT, et al. Metabolic syndrome and its component traits present gender-specific association with liver cancer risk: A prospective cohort study[J]. BMC Cancer, 2021, 21( 1): 1084. DOI: 10.1186/s12885-021-08760-1.
    [20]
    CHO Y, CHO EJ, YOO JJ, et al. Association between lipid profiles and the incidence of hepatocellular carcinoma: A nationwide population-based study[J]. Cancers(Basel), 2021, 13( 7): 1599. DOI: 10.3390/cancers13071599.
    [21]
    BORENA W, STROHMAIER S, LUKANOVA A, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578, 700 adults[J]. Int J Cancer, 2012, 131( 1): 193- 200. DOI: 10.1002/ijc.26338.
    [22]
    KASMARI AJ, WELCH A, LIU GD, et al. Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome[J]. Am J Med, 2017, 130( 6): 746. e1- 746. e 7. DOI: 10.1016/j.amjmed.2016.12.029.
    [23]
    SHEILA SHERLOCK D. Alcoholic liver disease[J]. Lancet, 1995, 345( 8944): 227- 229. DOI: 10.1016/s0140-6736(95)90226-0.
    [24]
    HALSTED CH. Nutrition and alcoholic liver disease[J]. Semin Liver Dis, 2004, 24( 3): 289- 304. DOI: 10.1055/s-2004-832941.
    [25]
    CHROSTEK L, SUPRONOWICZ L, PANASIUK A, et al.[J]. Clin Exp Med, 2014, 14( 4): 417- 421. DOI: 10.1007/s10238-013-0262-5.
    [26]
    GHADIR MR, RIAHIN AA, HAVASPOUR A, et al. The relationship between lipid profile and severity of liver damage in cirrhotic patients[J]. Hepat Mon, 2010, 10( 4): 285- 288.
    [27]
    PEREZ-MATOS MC, SANDHU B, BONDER A, et al. Lipoprotein metabolism in liver diseases[J]. Curr Opin Lipidol, 2019, 30( 1): 30- 36. DOI: 10.1097/MOL.0000000000000569.
    [28]
    LONG J, ZHANG CJ, ZHU N, et al. Lipid metabolism and carcinogenesis, cancer development[J]. Am J Cancer Res, 2018, 8( 5): 778- 791.
    [29]
    MICHIEL DF, OPPENHEIM JJ. Cytokines as positive and negative regulators of tumor promotion and progression[J]. Semin Cancer Biol, 1992, 3( 1): 3- 15.
    [30]
    MOTTA M, GIUGNO I, RUELLO P, et al. Lipoprotein(a) behaviour in patients with hepatocellular carcinoma[J]. Minerva Med, 2001, 92( 5): 301- 305.
  • Relative Articles

    [1]Ru JIA, Pingping ZHANG, Yuan YUAN, Yiyang HU, Qin FENG. Differences and application value of plasma bile acids in tumors of the liver[J]. Journal of Clinical Hepatology, 2024, 40(10): 2042-2048. doi: 10.12449/JCH241018
    [2]Afang SU, Xiaozhong JIANG, Yunshui ZHANG, Shouling WU, Guangjian LI. Influence of serum cumulative triglyceride exposure on the risk of acute pancreatitis[J]. Journal of Clinical Hepatology, 2024, 40(12): 2492-2498. doi: 10.12449/JCH241220
    [3]ZHANG ZhongLin, YUAN YuFeng. Key operating points of laparoscopic hepatectomy for liver tumor in difficult locations[J]. Journal of Clinical Hepatology, 2020, 36(12): 2663-2666. doi: 10.3969/j.issn.1001-5256.2020.12.006
    [4]Cui HaoZhe, Zhao Li, Sun MiaoMiao, Kang JianZhong, Wang WanChao, Liu SiQing, Cao LiYing. Influence of ideal cardiovascular health behaviors and factors on the onset of primary liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(2): 348-353. doi: 10.3969/j.issn.1001-5256.2020.02.023
    [5]Jiang Xin, Yan YongFeng, Zhong Rui, Peng Yan, Wang Min, Fu WenGuang, Tang XiaoWei. Association of hypertriglyceridemic waist phenotype with the severity and prognosis of acute pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 865-869. doi: 10.3969/j.issn.1001-5256.2020.04.031
    [6]Cui HaoZhe, Ma XiangMing, Liu Qian, Sun MiaoMiao, Zhao Li, Wang WanChao, Liu SiQing, Cao LiYing. Influence of the interaction between abdominal obesity and hypertriglyceridemia on the development of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1314-1319. doi: 10.3969/j.issn.1001-5256.2020.06.025
    [7]JIANG Xin, YAN YongFeng, ZHONG Rui, XU Huan, PENG Yan, TANG XiaoWei. Influence of serum triglyceride level on the prognosis of acute biliary pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(11): 2509-2514. doi: 10.3969/j.issn.1001-5256.2020.11.022
    [8]WANG WenHui, DUAN XuHua, LI Hao, LI FengYao, JU ShuGuang, WANG ManZhou, REN JianZhuang, HAN XinWei. Effect of arsenic trioxide-loaded CalliSpheres beads in the treatment of rabbits with VX2 liver tumor[J]. Journal of Clinical Hepatology, 2020, 36(12): 2730-2734. doi: 10.3969/j.issn.1001-5256.2020.12.018
    [9]He YaJing, Zhang ZhiMing, He WeiMeng, Hou JinLin. Epidemiological characteristics and prognosis of hepatocellular carcinoma: A single-center observational real-world cohort study of 1302 cases[J]. Journal of Clinical Hepatology, 2019, 35(5): 1002-1007. doi: 10.3969/j.issn.1001-5256.2019.05.014
    [10]Sun MiaoMiao, Cao LiYing, Sun WeiDong, Liu XiNing, Cui HaoZhe, Liang MingYang, Wei YaoChen, Wang WanChao, Liu SiQing. Association of serum high-density lipoprotein cholesterol with new-onset cholelithiasis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1745-1750. doi: 10.3969/j.issn.1001-5256.2019.08.019
    [11]Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
    [12]Ji RuiGeng, Zhu GuoLing, Zhang Bing, Sun Qiu, Zhao Li, Li GuangJian, Cao LiYing. Association between dyslipidemia and acute pancreatitis: A prospective cohort study[J]. Journal of Clinical Hepatology, 2019, 35(7): 1536-1540. doi: 10.3969/j.issn.1001-5256.2019.07.023
    [13]Wang ZhiYu, Gu SanWei, Chen XiaoQian, Cai YanJun. Clonorchiasis misdiagnosed as hepatic tumor: a case report[J]. Journal of Clinical Hepatology, 2018, 34(3): 602-603. doi: 10.3969/j.issn.1001-5256.2018.03.033
    [14]Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014
    [15]Hu XiaoYun, Sun Jian. Long-term follow-up cohort of hepatitis B in China: current status and perspectives[J]. Journal of Clinical Hepatology, 2017, 33(8): 1454-1457. doi: 10.3969/j.issn.1001-5256.2017.08.008
    [16]Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
    [17]Chen Hong, Wang Zhi, Wu Jian. Circulating tumor cells of hepatocellular carcinoma and their clinical implications[J]. Journal of Clinical Hepatology, 2011, 27(8): 796-800.
    [19]Yang BiWei, Gan YuHong, Ye ShengLong, Zhang BoHeng, Ren ZhengGang, Xia JingLin, Wang YanHong, Ge NingLing, Chen Yi, Li LiXin, Le Fan, Zhang Lan. Necrosis range and safety of radiofrequency combined with systemic chemotherapy and radiofrequency alone.[J]. Journal of Clinical Hepatology, 2004, 20(6): 364-365.
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 34.9 %FULLTEXT: 34.9 %META: 60.7 %META: 60.7 %PDF: 4.4 %PDF: 4.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 11.0 %其他: 11.0 %其他: 1.6 %其他: 1.6 %Baden: 0.4 %Baden: 0.4 %Bass Hill: 0.1 %Bass Hill: 0.1 %Central District: 0.6 %Central District: 0.6 %Kao-sung: 0.1 %Kao-sung: 0.1 %Kennedy Town: 0.1 %Kennedy Town: 0.1 %Malvern: 0.1 %Malvern: 0.1 %North Point: 0.1 %North Point: 0.1 %Saitama: 0.1 %Saitama: 0.1 %Taichung: 0.1 %Taichung: 0.1 %Westbury: 0.1 %Westbury: 0.1 %Wincanton: 0.1 %Wincanton: 0.1 %三明: 0.1 %三明: 0.1 %上塞纳省: 0.2 %上塞纳省: 0.2 %上海: 5.6 %上海: 5.6 %东京: 0.1 %东京: 0.1 %东莞: 0.4 %东莞: 0.4 %临沂: 0.1 %临沂: 0.1 %丽水: 0.1 %丽水: 0.1 %乌鲁木齐: 0.1 %乌鲁木齐: 0.1 %云浮: 0.1 %云浮: 0.1 %伊利诺伊州: 0.2 %伊利诺伊州: 0.2 %休斯敦: 0.1 %休斯敦: 0.1 %伦敦: 0.1 %伦敦: 0.1 %佛山: 0.4 %佛山: 0.4 %保定: 0.1 %保定: 0.1 %元朗新墟: 0.1 %元朗新墟: 0.1 %兰州: 0.2 %兰州: 0.2 %列治文山: 0.1 %列治文山: 0.1 %加利福尼亚: 0.1 %加利福尼亚: 0.1 %加利福尼亚州: 0.4 %加利福尼亚州: 0.4 %北京: 4.6 %北京: 4.6 %匹兹堡: 0.1 %匹兹堡: 0.1 %南京: 1.2 %南京: 1.2 %南宁: 0.4 %南宁: 0.4 %南昌: 0.1 %南昌: 0.1 %南通: 0.4 %南通: 0.4 %南阳: 0.1 %南阳: 0.1 %卡尔加里: 0.1 %卡尔加里: 0.1 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %卡罗尔顿: 0.1 %卡罗尔顿: 0.1 %卡马里奥: 0.1 %卡马里奥: 0.1 %厦门: 0.4 %厦门: 0.4 %台州: 0.1 %台州: 0.1 %吉隆坡: 0.3 %吉隆坡: 0.3 %周口: 0.2 %周口: 0.2 %呼和浩特: 0.2 %呼和浩特: 0.2 %咸阳: 0.1 %咸阳: 0.1 %圣何塞: 0.1 %圣何塞: 0.1 %埃克塞特: 0.1 %埃克塞特: 0.1 %埃德蒙顿: 0.1 %埃德蒙顿: 0.1 %墨尔本: 0.4 %墨尔本: 0.4 %大连: 0.1 %大连: 0.1 %大阪: 0.2 %大阪: 0.2 %天津: 0.2 %天津: 0.2 %孟买: 0.1 %孟买: 0.1 %宁波: 0.3 %宁波: 0.3 %安康: 0.1 %安康: 0.1 %宣城: 0.1 %宣城: 0.1 %密蘇里城: 0.5 %密蘇里城: 0.5 %巴黎: 0.3 %巴黎: 0.3 %常州: 0.8 %常州: 0.8 %常德: 0.2 %常德: 0.2 %广安: 0.1 %广安: 0.1 %广州: 1.4 %广州: 1.4 %廊坊: 0.1 %廊坊: 0.1 %延安: 0.1 %延安: 0.1 %弗吉: 0.1 %弗吉: 0.1 %弗吉尼亚: 0.1 %弗吉尼亚: 0.1 %张家口: 0.4 %张家口: 0.4 %徐州: 0.3 %徐州: 0.3 %忻州: 0.1 %忻州: 0.1 %悉尼: 0.1 %悉尼: 0.1 %惠州: 0.1 %惠州: 0.1 %成都: 0.7 %成都: 0.7 %扬州: 0.1 %扬州: 0.1 %拉斯维加斯: 0.2 %拉斯维加斯: 0.2 %新加坡: 0.1 %新加坡: 0.1 %无锡: 0.1 %无锡: 0.1 %昆明: 0.5 %昆明: 0.5 %曲靖: 0.1 %曲靖: 0.1 %朝阳: 0.1 %朝阳: 0.1 %杭州: 0.7 %杭州: 0.7 %格兰特县: 0.3 %格兰特县: 0.3 %桂林: 0.4 %桂林: 0.4 %武汉: 0.3 %武汉: 0.3 %氹仔: 0.1 %氹仔: 0.1 %汕头: 0.1 %汕头: 0.1 %沈阳: 0.4 %沈阳: 0.4 %沧州: 0.3 %沧州: 0.3 %泸州: 0.1 %泸州: 0.1 %洛杉矶: 0.2 %洛杉矶: 0.2 %洛阳: 0.2 %洛阳: 0.2 %济南: 0.3 %济南: 0.3 %海得拉巴: 0.3 %海得拉巴: 0.3 %深圳: 1.2 %深圳: 1.2 %温哥华: 0.1 %温哥华: 0.1 %温州: 0.4 %温州: 0.4 %湘潭: 0.1 %湘潭: 0.1 %滨州: 0.1 %滨州: 0.1 %漳州: 0.1 %漳州: 0.1 %潍坊: 0.2 %潍坊: 0.2 %澳门: 0.1 %澳门: 0.1 %珀斯: 0.1 %珀斯: 0.1 %班加罗尔: 0.1 %班加罗尔: 0.1 %盐城: 0.2 %盐城: 0.2 %石家庄: 0.4 %石家庄: 0.4 %纽卡斯尔: 0.1 %纽卡斯尔: 0.1 %绍兴: 0.4 %绍兴: 0.4 %绥化: 0.1 %绥化: 0.1 %芒廷维尤: 30.7 %芒廷维尤: 30.7 %芝加哥: 1.5 %芝加哥: 1.5 %苏州: 0.9 %苏州: 0.9 %莫斯科: 0.3 %莫斯科: 0.3 %萨斯卡通: 0.1 %萨斯卡通: 0.1 %葵涌: 0.3 %葵涌: 0.3 %西宁: 4.7 %西宁: 4.7 %西安: 0.4 %西安: 0.4 %诺沃克: 0.2 %诺沃克: 0.2 %贵阳: 0.3 %贵阳: 0.3 %资阳: 0.1 %资阳: 0.1 %赣州: 0.1 %赣州: 0.1 %赤峰: 0.2 %赤峰: 0.2 %运城: 0.4 %运城: 0.4 %邯郸: 0.1 %邯郸: 0.1 %郑州: 0.3 %郑州: 0.3 %都伯林: 0.1 %都伯林: 0.1 %重庆: 0.4 %重庆: 0.4 %金华: 0.2 %金华: 0.2 %银川: 0.1 %银川: 0.1 %镇江: 0.3 %镇江: 0.3 %长春: 9.0 %长春: 9.0 %长沙: 2.5 %长沙: 2.5 %防城港: 0.1 %防城港: 0.1 %青岛: 0.4 %青岛: 0.4 %香港: 0.2 %香港: 0.2 %马鞍山: 0.1 %马鞍山: 0.1 %黔南: 0.1 %黔南: 0.1 %其他其他BadenBass HillCentral DistrictKao-sungKennedy TownMalvernNorth PointSaitamaTaichungWestburyWincanton三明上塞纳省上海东京东莞临沂丽水乌鲁木齐云浮伊利诺伊州休斯敦伦敦佛山保定元朗新墟兰州列治文山加利福尼亚加利福尼亚州北京匹兹堡南京南宁南昌南通南阳卡尔加里卡纳塔克卡罗尔顿卡马里奥厦门台州吉隆坡周口呼和浩特咸阳圣何塞埃克塞特埃德蒙顿墨尔本大连大阪天津孟买宁波安康宣城密蘇里城巴黎常州常德广安广州廊坊延安弗吉弗吉尼亚张家口徐州忻州悉尼惠州成都扬州拉斯维加斯新加坡无锡昆明曲靖朝阳杭州格兰特县桂林武汉氹仔汕头沈阳沧州泸州洛杉矶洛阳济南海得拉巴深圳温哥华温州湘潭滨州漳州潍坊澳门珀斯班加罗尔盐城石家庄纽卡斯尔绍兴绥化芒廷维尤芝加哥苏州莫斯科萨斯卡通葵涌西宁西安诺沃克贵阳资阳赣州赤峰运城邯郸郑州都伯林重庆金华银川镇江长春长沙防城港青岛香港马鞍山黔南

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(5)

    Article Metrics

    Article views (677) PDF downloads(49) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return